VC Success in European Biotech & Healthcare

Life Sciences are not only critical for a healthier population, cutting-edge Biotech & Healthcare are also at the heart of a more innovative, competitive and stronger sovereign Europe. And that makes it a dynamic field for venture capital (VC) investment, and an unmissable sector for global investors looking for exposure to revolutionary European businesses and outstanding returns.

Europe has a long and illustrious history of pioneering Life Sciences discovery, fed by its world-class universities, research institutions, and established pharma sector. In the last decade alone, leaps forward have occurred in fields as diverse as oncology, gene therapy and vaccine development. Among those milestones, the development of an mRNA response to COVID-19 in 2021, co-led by German firm BioNTech, highlighted the knowledge and skills being leveraged at lightning speed in Europe to combat the pandemic. It also shone a fresh light on the strength and depth present in European biotech, and its place at the forefront of global Life Sciences – developing innovations that will save and change lives in Europe and around the globe.

In 2022, Invest Europe launched its first VC in Life Sciences online report to highlight venture capital investment in the Biotech & Healthcare sector in Europe, the high-value employment created at fast-growing companies, and the advances and discoveries being made at VC-backed start-ups. This is a fast-moving field, so in 2025 we updated our resources with the latest data and research to showcase new Biotech & Healthcare success stories across the continent from Amsterdam to Zurich, new job creation, and the growth in VC investment flowing into the sector.

Today, European Biotech & Healthcare is receiving new focus and support from policymakers, who view pioneering medical breakthroughs and developments as essential to European healthcare sovereignty and a stronger economy. In 2025, the European Commission launched its strategy to position the EU as the world’s most attractive place for Life Sciences by 2030. The programme, which is backed by more than €10 billion a year from the EU budget, will target accelerated innovation, improved market access for Life Sciences start-ups, and increased public trust in new technologies. The goal is to transform Europe’s strong existing knowledge base and scientific excellence into an ecosystem that maximises all the qualities and skills European Life Sciences have to offer.

In an uncertain and volatile world, often characterised by unpredictable policies towards health developments, funding and provision, Europe is emerging as a region of stability and security, as well as one with clear goals and ambitions. The result is a positive environment for VCs investing in Biotech & Healthcare innovators, as well as long-term investors seeking strong returns from the rising stars of European Life Sciences.